Dolby Family Ventures — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits.
BiotechDeep TechHealthtechKensington, US
Joseph Bondy-Denomy(Director)David Rabuka(Executive Officer, Director, Promoter)Karen Boezi(Director)
Co-investorsBerkeley Catalyst
Vacaville, US
Kirk Hawkins(Executive Officer, Director)Rich Bridge(Executive Officer)Thomas Wieners(Executive Officer)Katherine DeHoff(Executive Officer)
BoardLiu Dan(Director)Du Yang(Director)
Co-investorsSeraph Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.